Bioasis Technologies Inc. (OTCQB:BIOAF)(TSX.V:BTI) CEO Deborah Rathjen sat down with Proactive’s Christine Corrado at BIO CEO & Investor Conference in New York. Rathjen explains how the revenue potential for brain metastasis of breast cancer is $404M. Bioasis has developed its proprietary brain delivery technology, the xB3 platform, to make drugs brain-penetrant and deliver those therapies at a therapeutically relevant dose.
viewBioasis Technologies Inc.
Bioasis Technologies says revenue potential for brain metastasis of breast cancer is $404M
Quick facts: Bioasis Technologies Inc.
Price: 0.32 USD
OTCQB:BIOAF
Market: OTCQB
Market Cap: $21.71 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Bioasis Technologies Inc. named herein, including the promotion by the Company of Bioasis Technologies Inc. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Mining
Tesla’s 'battery day' next Tuesday could be ground-breaking for several...
1 day, 7 hours ago
Telecoms & Networks
LOOP Insights inks agreement with TELUS to conduct pilot across three retail...
2 days, 4 hours ago
Health
MMJ Group investees start capitalising on growing demand for cannabis products
5 days, 17 hours ago
